Outer Membrane Vesicles Protect Gram-Negative Bacteria against Host Defense Peptides.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
25 08 2021
Historique:
pubmed: 8 7 2021
medline: 13 1 2022
entrez: 7 7 2021
Statut: ppublish

Résumé

Host defense peptides (HDPs) are part of the innate immune system and constitute a first line of defense against invading pathogens. They possess antimicrobial activity against a broad spectrum of pathogens. However, pathogens have been known to adapt to hostile environments. Therefore, the bacterial response to treatment with HDPs was investigated. Previous observations suggested that sublethal concentrations of HDPs increase the release of outer membrane vesicles (OMVs) in Escherichia coli. First, the effects of sublethal treatment with HDPs CATH-2, PMAP-36, and LL-37 on OMV release of several Gram-negative bacteria were analyzed. Treatment with PMAP-36 and CATH-2 induced release of OMVs, but treatment with LL-37 did not. The OMVs were further characterized with respect to morphological properties. The HDP-induced OMVs often had disc-like shapes. The beneficial effect of bacterial OMV release was studied by determining the susceptibility of E. coli toward HDPs in the presence of OMVs. The minimal bactericidal concentration was increased in the presence of OMVs. It is concluded that OMV release is a means of bacteria to dispose of HDP-affected membrane. Furthermore, OMVs act as a decoy for HDPs and thereby protect the bacterium.

Identifiants

pubmed: 34232080
doi: 10.1128/mSphere.00523-21
pmc: PMC8386409
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimicrobial Cationic Peptides 0
Bacterial Outer Membrane Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0052321

Références

mBio. 2018 Oct 30;9(5):
pubmed: 30377277
Sci Rep. 2016 Sep 14;6:32948
pubmed: 27624595
Eur J Biochem. 1993 Jun 15;214(3):695-701
pubmed: 8319680
J Bacteriol. 1992 Feb;174(3):980-90
pubmed: 1370665
Biochim Biophys Acta. 2016 Mar;1858(3):546-66
pubmed: 26556394
J Bacteriol. 1978 Mar;133(3):1419-26
pubmed: 417067
FEMS Microbiol Rev. 2006 May;30(3):382-403
pubmed: 16594963
Front Microbiol. 2021 Feb 04;12:629090
pubmed: 33613498
Sci Rep. 2017 Nov 7;7(1):14637
pubmed: 29116115
J Bacteriol. 2000 Jul;182(14):4077-86
pubmed: 10869088
PLoS One. 2015 Jun 25;10(6):e0130528
pubmed: 26110524
J Bacteriol. 2006 Aug;188(15):5385-92
pubmed: 16855227
J Endotoxin Res. 2001;7(1):63-8
pubmed: 11521085
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Mol Immunol. 2009 Apr;46(7):1517-26
pubmed: 19187966
Anal Chem. 2006 Feb 1;78(3):779-87
pubmed: 16448051
PLoS Pathog. 2009 Nov;5(11):e1000660
pubmed: 19915718
FEBS J. 2005 Sep;272(17):4398-406
pubmed: 16128809
J Bacteriol. 1949 Aug;58(2):127-34
pubmed: 18138140
Drug Resist Updat. 2016 May;26:43-57
pubmed: 27180309
J Bacteriol. 1967 Oct;94(4):1216-24
pubmed: 4167588
BMC Microbiol. 2011 Dec 01;11:258
pubmed: 22133164
Nat Rev Microbiol. 2006 Jul;4(7):529-36
pubmed: 16778838
PLoS Pathog. 2018 Aug 20;14(8):e1007153
pubmed: 30125334
PLoS One. 2014 Jan 21;9(1):e86364
pubmed: 24466055
Virulence. 2021 Dec;12(1):1452-1468
pubmed: 34053396
FEMS Microbiol Rev. 2016 Jan;40(1):133-59
pubmed: 25862689
Philos Trans R Soc Lond B Biol Sci. 2016 May 26;371(1695):
pubmed: 27160595
J Innate Immun. 2009;1(3):202-14
pubmed: 20375578
Chem Rev. 2017 Mar 22;117(6):4669-4713
pubmed: 28177242
Nat Rev Microbiol. 2005 Mar;3(3):238-50
pubmed: 15703760
Nat Rev Drug Discov. 2020 May;19(5):311-332
pubmed: 32107480
J Biol Chem. 2006 Jun 30;281(26):18135-44
pubmed: 16632471
Sci Rep. 2019 Mar 18;9(1):4780
pubmed: 30886247
Biophys J. 2001 Jul;81(1):243-54
pubmed: 11423410
J Mass Spectrom. 2004 May;39(5):505-13
pubmed: 15170746
FEMS Microbiol Rev. 2015 Nov;39(6):812-22
pubmed: 26195616
J Bacteriol. 1978 Oct;136(1):280-5
pubmed: 361695
Front Microbiol. 2011 Jun 01;2:118
pubmed: 21687428
Mol Cell. 2014 Apr 24;54(2):321-8
pubmed: 24766896
Cell Immunol. 2012 Nov;280(1):22-35
pubmed: 23246832
J Dent Res. 2017 Mar;96(3):254-260
pubmed: 27872334
Microbiology (Reading). 2020 Aug;166(8):751-758
pubmed: 32463354

Auteurs

Melanie D Balhuizen (MD)

Section of Molecular Host Defence, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Albert van Dijk (A)

Section of Molecular Host Defence, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Jeroen W A Jansen (JWA)

Section of Cell Biology, Metabolism and Cancer, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Chris H A van de Lest (CHA)

Section of Cell Biology, Metabolism and Cancer, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Edwin J A Veldhuizen (EJA)

Section of Immunology, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Henk P Haagsman (HP)

Section of Molecular Host Defence, Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH